Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
51.37 (1y: +22%)
Market Cap 57.88 B P/E(ttm) 12.30
Enterprise Value 59.71 B P/B 4.10
LLY- NYSE (USA)
Eli Lilly and Company
  • Currently 2.5/5
Business Predictability Rank: 2.5-Star (On Watch)
Back Testing Results:
Average gain of all 2.5-Star stocks: 7.3% per year.
% of Stocks that are in still loss if held for 10yrs: 18%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$51.37
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 1.028
LLY's Cash to Debt is ranked higher than
59% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. LLY: 1.028 )
LLY' s 10-Year Cash to Debt Range
Min: 0.57   Max: 1.64
Current: 1.03
0.57
1.64
Equity to Asset 0.429
LLY's Equity to Asset is ranked higher than
50% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. LLY: 0.429 )
LLY' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.51
Current: 0.43
0.23
0.51
Interest Coverage 74.3
LLY's Interest Coverage is ranked higher than
73% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.70 vs. LLY: 74.3 )
LLY' s 10-Year Interest Coverage Range
Min: 18   Max: No Debt
Current: 74.3
F-Score: 6
Z-Score: 4.21
M-Score: -2.3
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 23.90
LLY's Operating margin (%) is ranked higher than
91% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.80 vs. LLY: 23.90 )
LLY' s 10-Year Operating margin (%) Range
Min: 3.4   Max: 33.6
Current: 23.9
3.4
33.6
Net-margin (%) 18.1
LLY's Net-margin (%) is ranked higher than
89% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. LLY: 18.1 )
LLY' s 10-Year Net-margin (%) Range
Min: -10.2   Max: 28.2
Current: 18.1
-10.2
28.2
ROE (%) 27.7
LLY's ROE (%) is ranked higher than
98% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. LLY: 27.7 )
LLY' s 10-Year ROE (%) Range
Min: -30.8   Max: 54.3
Current: 27.7
-30.8
54.3
ROA (%) 11.9
LLY's ROA (%) is ranked higher than
93% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. LLY: 11.9 )
LLY' s 10-Year ROA (%) Range
Min: -7.1   Max: 21.2
Current: 11.9
-7.1
21.2
ROC (Joel Greenblatt) (%) 80.30
LLY's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.40 vs. LLY: 80.30 )
LLY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 8.8   Max: 130.6
Current: 80.3
8.8
130.6
Revenue Growth (%) 0.4
LLY's Revenue Growth (%) is ranked higher than
67% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. LLY: 0.4 )
LLY' s 10-Year Revenue Growth (%) Range
Min: 0.4   Max: 8.6
Current: 0.4
0.4
8.6
EBITDA Growth (%) -0.5
LLY's EBITDA Growth (%) is ranked lower than
52% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. LLY: -0.5 )
LLY' s 10-Year EBITDA Growth (%) Range
Min: -19.7   Max: 39
Current: -0.5
-19.7
39
EPS Growth (%) -1.8
LLY's EPS Growth (%) is ranked lower than
54% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. LLY: -1.8 )
LLY' s 10-Year EPS Growth (%) Range
Min: -10.2   Max: 14
Current: -1.8
-10.2
14
ยป LLY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

LLY Guru Trades in Q2 2012

Louis Moore Bacon 4,755 sh (New)
Ray Dalio 73,442 sh (New)
Andreas Halvorsen 3,492,300 sh (New)
Manning & Napier Advisors, Inc 153,996 sh (+74.77%)
Jim Simons 11,064,705 sh (+22.55%)
Mario Gabelli 216,770 sh (+7.54%)
John Hussman 2,251,000 sh (unchged)
Alan Fournier 1,138,200 sh (unchged)
Louis Moore Bacon 250,000 sh (unchged)
Vanguard Health Care Fund 15,864,300 sh (unchged)
Murray Stahl 43,136 sh (unchged)
Steven Cohen Sold Out
David Dreman Sold Out
Chris Davis 325,829 sh (-3.1%)
Bill Frels 298,871 sh (-3.81%)
Pioneer Investments 932,801 sh (-6.14%)
Dodge & Cox 36,960 sh (-7.75%)
Charles Brandes 3,660,526 sh (-9.04%)
PRIMECAP Management 49,021,729 sh (-10.48%)
Jeremy Grantham 2,215,959 sh (-10.9%)
Paul Tudor Jones 13,000 sh (-11.56%)
HOTCHKIS & WILEY 1,606,080 sh (-44.94%)
Joel Greenblatt 33,227 sh (-53.72%)
» More
Q3 2012

LLY Guru Trades in Q3 2012

George Soros 190,000 sh (New)
Steven Cohen 26,581 sh (New)
Ruane Cunniff 4,321 sh (New)
Paul Tudor Jones 142,800 sh (+998.46%)
Louis Moore Bacon 21,482 sh (+351.78%)
Andreas Halvorsen 4,939,200 sh (+41.43%)
Manning & Napier Advisors, Inc 165,267 sh (+7.32%)
HOTCHKIS & WILEY 1,653,998 sh (+2.98%)
Murray Stahl 43,136 sh (unchged)
Alan Fournier 1,138,200 sh (unchged)
Dodge & Cox 36,560 sh (-1.08%)
PRIMECAP Management 48,317,289 sh (-1.44%)
Signature Select Canadian Fund 937,600 sh (-2.03%)
Bill Frels 292,475 sh (-2.14%)
Vanguard Health Care Fund 15,364,300 sh (-3.15%)
Chris Davis 313,054 sh (-3.92%)
Joel Greenblatt 31,327 sh (-5.72%)
Jeremy Grantham 1,967,589 sh (-11.21%)
Mario Gabelli 181,100 sh (-16.46%)
Jim Simons 9,104,405 sh (-17.72%)
Pioneer Investments 756,585 sh (-18.89%)
John Hussman 1,751,000 sh (-22.21%)
Charles Brandes 2,717,962 sh (-25.75%)
Ray Dalio 43,642 sh (-40.58%)
» More
Q4 2012

LLY Guru Trades in Q4 2012

Steven Cohen 169,093 sh (+536.14%)
Louis Moore Bacon 100,000 sh (+365.51%)
Manning & Napier Advisors, Inc 166,537 sh (+0.77%)
PRIMECAP Management 48,617,689 sh (+0.62%)
Jeremy Grantham 2,165,154 sh (unchged)
Vanguard Health Care Fund 15,364,300 sh (unchged)
Ruane Cunniff Sold Out
Joel Greenblatt Sold Out
Andreas Halvorsen Sold Out
Dodge & Cox 36,060 sh (-1.37%)
Bill Frels 286,522 sh (-2.04%)
HOTCHKIS & WILEY 1,557,102 sh (-5.86%)
Chris Davis 291,669 sh (-6.83%)
Mario Gabelli 164,700 sh (-9.06%)
Jim Simons 8,108,905 sh (-10.93%)
Murray Stahl 38,212 sh (-11.42%)
Charles Brandes 2,239,053 sh (-17.62%)
Pioneer Investments 616,496 sh (-18.52%)
John Hussman 1,401,000 sh (-19.99%)
George Soros 100,000 sh (-47.37%)
Ray Dalio 13,942 sh (-68.05%)
Paul Tudor Jones 10,200 sh (-92.86%)
» More
Q1 2013

LLY Guru Trades in Q1 2013

Ken Fisher 3,900 sh (New)
Joel Greenblatt 3,961 sh (New)
Jeremy Grantham 3,857,862 sh (+78.18%)
Pioneer Investments 951,265 sh (+54.3%)
Steven Cohen 238,226 sh (+40.88%)
Jim Simons 10,555,805 sh (+30.18%)
Manning & Napier Advisors, Inc 179,863 sh (+8%)
Dodge & Cox 36,060 sh (unchged)
Vanguard Health Care Fund 15,364,300 sh (unchged)
Louis Moore Bacon Sold Out
Ray Dalio Sold Out
Bill Frels 284,878 sh (-0.57%)
Chris Davis 283,709 sh (-2.73%)
PRIMECAP Management 46,844,876 sh (-3.65%)
Murray Stahl 36,136 sh (-5.43%)
Charles Brandes 2,037,064 sh (-9.02%)
Mario Gabelli 142,500 sh (-13.48%)
Paul Tudor Jones 8,800 sh (-13.73%)
George Soros 55,000 sh (-45%)
John Hussman 601,000 sh (-57.1%)
HOTCHKIS & WILEY 407,650 sh (-73.82%)
» More
» Details

Insider Trades

Latest Guru Trades with LLY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 Reduce -57.1%1.03%$49.32 - $56.79 $ 52.35-3%601000
George Soros 2013-03-31 Reduce -45%0.03%$49.32 - $56.79 $ 52.35-3%55000
Ray Dalio 2013-03-31 Sold Out 0.01%$49.32 - $56.79 $ 52.35-3%0
Joel Greenblatt 2013-03-31 New Buy0.01%$49.32 - $56.79 $ 52.35-3%3961
Joel Greenblatt 2012-12-31 Sold Out 0.1%$45.91 - $53.81 $ 52.356%0
George Soros 2012-12-31 Reduce -47.37%0.07%$45.91 - $53.81 $ 52.356%100000
Ray Dalio 2012-12-31 Reduce -68.05%0.02%$45.91 - $53.81 $ 52.356%13942
Ruane Cunniff 2012-12-31 Sold Out 0.0016%$45.91 - $53.81 $ 52.356%0
Charles Brandes 2012-09-30 Reduce -25.75%0.41%$42 - $47.63 $ 52.3518%2717962
John Hussman 2012-09-30 Reduce -22.21%0.4%$42 - $47.63 $ 52.3518%1751000
George Soros 2012-09-30 New Buy0.15%$42 - $47.63 $ 52.3518%190000
Ray Dalio 2012-09-30 Reduce -40.58%0.02%$42 - $47.63 $ 52.3518%43642
Ruane Cunniff 2012-09-30 New Buy$42 - $47.63 $ 52.3518%4321
Joel Greenblatt 2012-06-30 Reduce -53.72%0.13%$39.49 - $42.66 $ 52.3528%33227
Ray Dalio 2012-06-30 New Buy0.05%$39.49 - $42.66 $ 52.3528%73442
David Dreman 2012-06-30 Sold Out 0.02%$39.49 - $42.66 $ 52.3528%0
Premium More recent guru trades are included for Premium Members only!!
ยป Financial Charts

Peter Lynch Chart

Top Ranked Articles about Eli Lilly and Company

52-Week High
March 11, 2013
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs. Read more...
Guru Stocks at 52-Week High: CMCSA, LLY, DGX, IP, ROP
October 8, 2012
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs: Comcast Corporation (CMCSA), Eli Lilly & Co. (LLY), Quest Diagnostics Inc. (DGX), International Paper Company (IP) and Roper Industries Inc. (ROP). Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 12.50
LLY's P/E(ttm) is ranked higher than
88% of the 497 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.30 vs. LLY: 12.50 )
LLY' s 10-Year P/E(ttm) Range
Min: 7.44   Max: 51.33
Current: 12.5
7.44
51.33
P/B 4.10
LLY's P/B is ranked higher than
50% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.46 vs. LLY: 4.10 )
LLY' s 10-Year P/B Range
Min: 2.4   Max: 21.26
Current: 4.1
2.4
21.26
P/S 2.60
LLY's P/S is ranked higher than
65% of the 654 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.68 vs. LLY: 2.60 )
LLY' s 10-Year P/S Range
Min: 1.48   Max: 11.26
Current: 2.6
1.48
11.26
PFCF 15.50
LLY's PFCF is ranked higher than
83% of the 399 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.96 vs. LLY: 15.50 )
LLY' s 10-Year PFCF Range
Min: 5.04   Max: 452.77
Current: 15.5
5.04
452.77
EV-to-EBIT 10.8
LLY's EV-to-EBIT is ranked higher than
83% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.43 vs. LLY: 10.8 )
LLY' s 10-Year EV-to-EBIT Range
Min: 5.8   Max: 70.3
Current: 10.8
5.8
70.3
PEG 0.4
LLY's PEG is ranked higher than
96% of the 263 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.22 vs. LLY: 0.4 )
LLY' s 10-Year PEG Range
Min: 0.4   Max: 461.86
Current: 0.4
0.4
461.86
Shiller P/E 16.8
LLY's Shiller P/E is ranked lower than
100% of the Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: vs. LLY: 16.8 )
LLY' s 10-Year Shiller P/E Range
Min: 12.03   Max: 29.28
Current: 16.8
12.03
29.28

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 3.80
LLY's Dividend Yield is ranked higher than
95% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.37 vs. LLY: 3.80 )
LLY' s 10-Year Dividend Yield Range
Min: 0.91   Max: 6.79
Current: 3.8
0.91
6.79
Dividend Payout 0.4734
LLY's Dividend Payout is ranked higher than
50% of the 338 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. LLY: 0.4734 )
LLY' s 10-Year Dividend Payout Range
Min: 0.37   Max: 0.86
Current: 0.47
0.37
0.86
Yield on cost (5-Year) 3.95
LLY's Yield on cost (5-Year) is ranked higher than
92% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.29 vs. LLY: 3.95 )
LLY' s 10-Year Yield on cost (5-Year) Range
Min: 0.95   Max: 7.07
Current: 3.95
0.95
7.07
Share Buyback Rate -0.4
LLY's Share Buyback Rate is ranked higher than
57% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. LLY: -0.4 )
LLY' s 10-Year Share Buyback Rate Range
Min: 0.5   Max: -0.4
Current: -0.4

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 14.1
LLY's Price/Net Current Asset Value is ranked higher than
66% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.20 vs. LLY: 14.1 )
LLY' s 10-Year Price/Net Current Asset Value Range
Min: 8.9   Max: 53.5
Current: 14.1
8.9
53.5
Price/Tangible Book 5.9
LLY's Price/Tangible Book is ranked lower than
57% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. LLY: 5.9 )
LLY' s 10-Year Price/Tangible Book Range
Min: 5.1   Max: 16.9
Current: 5.9
5.1
16.9
Price/DCF (Projected) 1
LLY's Price/DCF (Projected) is ranked higher than
86% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. LLY: 1 )
LLY' s 10-Year Price/DCF (Projected) Range
Min: 0.7   Max: 2.5
Current: 1
0.7
2.5
Price/Median PS Value 0.7
LLY's Price/Median PS Value is ranked higher than
91% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. LLY: 0.7 )
LLY' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 2.4
Current: 0.7
0.4
2.4
Price/Peter Lynch Fair Value 0.7
LLY's Price/Peter Lynch Fair Value is ranked higher than
91% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. LLY: 0.7 )
LLY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.8   Max: 3.5
Current: 0.7
0.8
3.5
Price/Graham Number 1.9
LLY's Price/Graham Number is ranked higher than
67% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.00 vs. LLY: 1.9 )
LLY' s 10-Year Price/Graham Number Range
Min: 1.3   Max: 5
Current: 1.9
1.3
5
Earnings Yield (Greenblatt) 9.30
LLY's Earnings Yield (Greenblatt) is ranked higher than
87% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. LLY: 9.30 )
LLY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 17.2
Current: 9.3
1.4
17.2
Forward Rate of Return (Yacktman) 25.86
LLY's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. LLY: 25.86 )
LLY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.8   Max: 27.4
Current: 25.86
-0.8
27.4

Business Description

Eli Lilly and Company was incorporated in 1901 in Indiana for the drug manufacturing business founded in Indianapolis, Indiana, in 1876. The Company discovers, develops, manufactures, and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. The Company's products include: Neurosciences products including; Zyprexa(r), for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Zyprexa Relprevvtm, a long-acting intramuscular injection formulation of Zyprexa. Cymbalta(r), for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera(r), for the treatment of attention-deficit hyperactivity disorder in children, adolescents and adults; Prozac(r), for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder; Symbyax(r), for the treatment of bipolar depression: Endocrinology products including; Humalog(r) , Humalog Mix 75/25(r), and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin(r), for the treatment of diabetes; Byetta(r), for the treatment of type 2 diabetes; Actos(r), for the treatment of type 2 diabetes; Evista(r), for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer; Forteo(r), for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; Humatrope(r), for the treatment of human growth hormone deficiency and idiopathic short stature. Oncology products, including Gemzar(r), for the treatment of pancreatic cancer; Alimta(r), for the first-line treatment, in combination with another agent, of non-small cell lung cancer for patients with non-squamous histology; for the second-line treatment of non-small cell lung cancer; Erbitu(r) is indicated both as a single agent and with other chemotherapy agents for the treatment of certain types of colorectal cancers and as a single agent or in combination with radiation therapy for head and neck cancers. Cardiovascular products, including Cialis(r), for the treatment of erectile dysfunction; Efient(r), for the prevention of atherothrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary invention; ReoPro(r), for use as an adjunct to percutaneous coronary intervention, including patients undergoing angioplasty, atherectomy or stent placement; Xigris(r), for the treatment of adults with severe sepsis at high risk of death. Animal health products, including Rumensin(r), a cattle feed additive that improves feed efficiency and growth and also controls and prevents coccidiosis; Tylan(r), an antibiotic used to control certain diseases in cattle, swine, and poultry; Micotil(r), Pulmotil(r), and Pulmotil AC(r), antibiotics used to treat respiratory
Company Website
SEC Reports
Industry: Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS
Traded in other countries:LEL.UK, LLY.Switzerland, LLY.Germany
ยป More Articles for LLY

Headlines

Articles On GuruFocus.com
Johnson & Johnson (JNJ) Dividend Stock Analysis May 23 2013 
20 Best-Yielding Health Care Stocks - Less Volatile Than the Market Apr 02 2013 
Abbvie Inc. (ABBV) Dividend Stock Analysis Mar 22 2013 
52-Week High Mar 11 2013 
Abbott Laboratories (ABT) Dividend Stock Analysis Dec 27 2012 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 23 2012 
Johnson & Johnson (JNJ) Dividend Stock Analysis Nov 15 2012 
Any More Upside in Eli Lilly? Oct 10 2012 
Guru Stocks at 52-Week High: CMCSA, LLY, DGX, IP, ROP Oct 08 2012 
Lilly Looms Over Patent Precipice Sep 30 2012 

More From Our Partners
FDA Probes 2 Deaths Possibly Related to Lilly Drug Jun 18 2013 - FOXBUSINESS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK